An unloved health-care stock gets welcome nod in AI-obsessed market - CNBC

The loudest investments aren't always the smartest ones.

While everyone chases the next shiny AI tool, Wall Street just upgraded Johnson & Johnson — a company that quietly keeps solving real problems while the hype machine looks elsewhere.

Sound familiar?

You've probably bought into the hype before. That AI tool collecting dust, the $200/month subscription nobody touches. It's not because you made a bad decision — it's because you were sold a solution before anyone understood your actual problem.

Here's the real lesson from the J&J story: boring and reliable beats flashy and overhyped every single time.

The businesses winning with AI right now aren't the ones who bought the most talked-about platform. They're the ones who picked one specific, painful problem — a repetitive task, a slow process, a customer service bottleneck — and solved just that. Nothing more.

That's your starting point.

Pick one workflow that annoys your team every single week. Just one. Then ask whether a simple AI tool can reduce that specific friction. No ripping apart systems. No big budget. No coding.

One problem. One solution. Measurable result within 30 days.

What's the AI tool you bought that your team never actually adopted?

#AIStrategy #SmallBusiness #BusinessGrowth #AIImplementation

Original Source

Health-care stocks aren't getting much of a look in this AI-driven market. That makes a Wall Street upgrade of Johnson & Johnson a bit of an ...